Atjaunināt sīkdatņu piekrišanu

New Directions in Bioprocess Modeling and Control: Maximizing Process Analytical Technology Benefits 2nd Revised edition [Mīkstie vāki]

  • Formāts: Paperback / softback, 468 pages, weight: 1024 g
  • Izdošanas datums: 30-Aug-2022
  • Izdevniecība: Instrument Society of America
  • ISBN-10: 1643311042
  • ISBN-13: 9781643311043
  • Mīkstie vāki
  • Cena: 157,45 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 468 pages, weight: 1024 g
  • Izdošanas datums: 30-Aug-2022
  • Izdevniecība: Instrument Society of America
  • ISBN-10: 1643311042
  • ISBN-13: 9781643311043
This book provides practical, comprehensive knowledge on how to use the advances in analytical measurements and basic and advanced control to improve batch profiles and endpoint consistency. The consequential integration of measurements, models, and controls into a digital twin with recently developed blocks to provide profiles and predict endpoints enables:

Developing dynamic models from trend charts that are used for experiment design, diagnosing the sources of limitations and inconsistences, and developing and testing solutions 500 times real time without interfering with existing plant operation. Comprehensive views of basic process control with the possibilities of model predictive control to control and optimize batch profiles by non-intrusive development and confirmation. The ability to determine how to maximize the performance of bioreactors, which are often the bottleneck and the key to product quality and consistency, without tests or trials in the actual plant.

The resulting improvements in batch cycle time and consistency can be designed, tested, quantified, and confirmed; and operators can be trained independently of actual plant operation. The benefit from the elimination of a bad batchparticularly for new biologicsis potentially worth ten or more million dollars.